Grant: Operating Grant
McMaster University
$86,439.00
Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
EF 2012-13
Résumé
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. High blood pressure and heart failure are common problems in patients that require dialysis and are key causes of death due to heart disease. Eplerenone is a drug that is very effective in reducing blood pressure and improving heart failure in patients that do not require dialysis. There is currently no evidence to tell physicians whether eplerenone would have similar benefits in patients that require dialysis. This evidence can only be reliably generated by performing a large scale study. Before such a study is undertaken, we must determine whether eplerenone will be well tolerated and safe in patients that require dialysis. We will perform a pilot trial called the Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE) to determine if eplerenone is a well tolerated, safe medication to study in a very large, global study that will show whether or not eplerenone reduces important outcomes for patients like death from heart causes.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
267803
Name
Walsh Michael W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - D: Cardiovascular Systems
Projecttitle
Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$86,439
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Aldosterone; End-Stage Renal Disease; Eplerenone; Hemodialysis; Randomized Controlled Trial
Abstract
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. High blood pressure and heart failure are common problems in patients that require dialysis and are key causes of death due to heart disease. Eplerenone is a drug that is very effective in reducing blood pressure and improving heart failure in patients that do not require dialysis. There is currently no evidence to tell physicians whether eplerenone would have similar benefits in patients that require dialysis. This evidence can only be reliably generated by performing a large scale study. Before such a study is undertaken, we must determine whether eplerenone will be well tolerated and safe in patients that require dialysis. We will perform a pilot trial called the Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE) to determine if eplerenone is a well tolerated, safe medication to study in a very large, global study that will show whether or not eplerenone reduces important outcomes for patients like death from heart causes.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Walsh, Michael W; Wald, Ron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $86,439~ $0~